Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPF CBP1
Description: Selective CBP/p300 bromodomain inhibitor
Chemical Name: 5-(Dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-[2-(4-propoxyphenyl)ethyl]-1H-1,3-benzodiazole
Purity: ≥98% (HPLC)
Biological Activity for PF CBP1
Selective CBP/p300 bromodomain inhibitor (IC50 values are 125 and 363 nM, respectively). Exhibits >100-fold selectivity for CBP over BRD4. Also exhibits selectivity over a panel of other bromodomains. Reduces LPS-induced IL-1β, IL-6 and IFN-β expression in macrophages in vitro. Also downregulates RGS4 expression in primary cortical neurons in vitro.
Negative Control also available.
Licensing Information
Sold for research purposes under agreement from Pfizer Inc.
External Portal Informaiton for PF CBP1
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of PF CBP1 is reviewed on the chemical probes website.
Technical Data for PF CBP1
| M. Wt | 488.62 |
| Formula | C29H36N4O3 |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1962928-21-7 |
| PubChem ID | 119081417 |
| InChI Key | CGWBJJZOKGZCSJ-UHFFFAOYSA-N |
| Smiles | CC(ON=C1C)=C1C2=CC(N=C(CCC3=CC=C(OCCC)C=C3)N4CCN5CCOCC5)=C4C=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for PF CBP1
References for PF CBP1
References are publications that support the biological activity of the product.
Chekler et al (2015) Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities. Chem.Biol. 22 1588 PMID: 26670081
View Related Products by Target
View Related Products by Product Action
Keywords: PF CBP1, PF CBP1 supplier, PFCBP1, selective, CBP, CREBBP, EP300, bromodomains, inhibitors, inhibits, Bromodomains, 5801, Tocris Bioscience
Citations for PF CBP1
Citations are publications that use Tocris products.
Currently there are no citations for PF CBP1.
Reviews for PF CBP1
There are currently no reviews for this product. Be the first to review PF CBP1 and earn rewards!
Have you used PF CBP1?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Stem Cell Research Product Guide
This product guide provides a background to the use of small molecules in stem cell research and lists over 200 products for use in:
- Self-renewal and Maintenance
- Differentiation
- Reprogramming
- Organoid Generation
- GMP and Ancillary Material Grade Products
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.